Starling Oncology, Inc. Accounts Receivable, Fair Value Disclosure
Starling Oncology, Inc. (STLN) had Accounts Receivable, Fair Value Disclosure of $34.82 million as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:AccountsReceivableFairValueDisclosure · last filed 2022-11-09
- 2022-09-30: Accounts Receivable, Fair Value Disclosure $34.82M.
- 2022-06-30: Accounts Receivable, Fair Value Disclosure $28.95M.
- 2022-03-31: Accounts Receivable, Fair Value Disclosure $24.51M.
- 2021-12-31: Accounts Receivable, Fair Value Disclosure $20.01M.
| Period end | Accounts Receivable, Fair Value Disclosure |
|---|---|
| 2022-09-30 | $34.82M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $28.95M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $24.51M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $20.01M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $17.15M 10-K · filed 2022-03-11 |